Life sciences · Journal article

Time for Precision: Rethinking antimicrobial use to combat AMR globally

Cambridge Prisms Antimicrobial Resistance · August 6, 2026

Expert Guidance Why this matters to you Expert discussion

A consensus or society position rather than new primary data.

AI Summary

This is a policy and strategic opinion article advocating a shift toward precision antimicrobial approaches guided by rapid diagnostics, modelled on oncology's integration of precision medicine with commodity agents. It proposes reimbursement and infrastructure changes (via initiatives such as PACE) to overcome economic barriers to AMR drug development, but presents no original clinical trial data, outcomes, or quantified evidence of efficacy.

What was studied

Journal article.

Key findings

Precision antimicrobials combined with commodity agents and rapid diagnostics are proposed as a model to target resistant infections more effectively Oncology's approach of integrating precision medicines with commodity anti-cancer agents has achieved significant extension in survival and created new biotech subsectors PACE (Pathways to Antimicrobial Clinical Efficacy) is identified as a global AMR R&D platform offering infrastructure and wrap-around support for diagnostics and therapeutics development

Safety

No quantified estimates of mortality reduction, clinical cure rates, or resistance suppression

Who this may help

This opinion recommends clinicians and policymakers adopt a precision medicine framework for antimicrobial selection, underpinned by rapid diagnostics and tailored reimbursement models, rather than relying on continued development of broad-spectrum agents. However, the recommendation rests on analogy and policy logic rather than published clinical trial evidence of improved patient outcomes.

Plain-language summary

A narrative expert opinion and policy recommendation on reshaping antimicrobial development strategy, not a research study with empirical evidence of clinical outcomes.

Clinical bottom line

Caveats

No empirical clinical trial data, efficacy metrics, or patient outcomes reported
Argument relies on analogy to oncology without direct evidence of precision antimicrobial performance in comparative trials
No quantified estimates of mortality reduction, clinical cure rates, or resistance suppression
Source does not provide evidence that proposed reimbursement frameworks have been implemented or validated

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

No empirical study design; this is a narrative opinion piece.

Directness

limited

Argues by analogy to oncology; no direct clinical evidence on precision antimicrobial efficacy.

Consistency

insufficient

No comparison to other evidence or conflicting studies presented.

Risk of bias

insufficient

No experimental data or bias assessment applicable to narrative opinion.

Sample adequacy

insufficient

No study population or sample; editorial framing only.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

The rise of antimicrobial resistance (AMR), driven by relentless microbial evolution, threatens the foundations of global healthcare.Rather than following the so far undeliverable promise of evermore broad-spectrum antibiotics, infectious disease treatment can follow the example of oncology, which has, over a short period, augmented a platform of commodity anti-cancer agents with precision medicines and diagnostics to combat cancer evolution on a personalised basis.It is this shift that has allowed a significant extension in survival and has created entirely new subsectors of biotech.Sophisticated thinking and concerted action has also made changes to clinical practice and pathways.Applying these principles, precision antimicrobials, guided by rapid diagnostics and used alongside commodity products, offer a way to target resistant infections more effectively.Moreover, thinking about multidrug resistance medicines as precision agents for rare occurrences opens up precented reimbursement frameworks that can breaking the economic logjam that has smothered the sector for a generation.This is not the science of the future.The foundations of precision antimicrobial approaches are already emerging, with an ecosystem of initiatives to wrap around and support their development.Among these, PACE (Pathways to Antimicrobial Clinical Efficacy), a global AMR R&D platform, that funds and offers wrap-around support for the development of new diagnostics and therapeutics, providing crucial infrastructure for emerging pipelines.Precision approaches have the potential to save lives that could otherwise be lost to Downloaded from https://www.cambridge.org/core.07

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Beverley IsherwoodChristopher Molloy